MyoMobile Study: App-based Activity Coaching in Patients with Heart Failure and Preserved Ejection Fraction

Johannes Gutenberg University Mainz193 enrolled

Overview

The MyoMobile study is a single-center, randomized, controlled three-armed cohort study with prospective data collection to investigate the effect of a personalized mobile health intervention compared to usual care on the physical activity levels in patients with heart failure and preserved ejection fraction.

Heart failure (HF) affects more than 15 million people in Europe and represents the leading cause of hospitalization. The prevalence of HF is increasing, which has been attributed to an ageing population with subsequently higher prevalence of predisposing risk factors (e.g. arterial hypertension, type-2-diabetes, obesity), a better survival, and more effective treatment of precursors (e.g. myocardial infarction). In the community, heart failure with preserved ejection fraction (HFpEF) is the most common HF phenotype. Currently, the benefit of medical therapies is limited to patients with heart failure with reduced ejection fraction (HFrEF) only, whereas no specific medical therapy is currently approved for patients with HFpEF. In HF patients, physical inactivity and a sedentary lifestyle lead to disease progression and increased mortality, and an increase of physical activity is positively correlated with improved outcome. Guidelines from the Heart Failure Society of America recommend at least 30 minutes of moderate-intensity activity for ≥ 5 days/week (i.e. at least 150 min/week). Unfortunately, exercise recommendations are poorly implemented in daily clinical practice and even patients enrolled in supervised exercise training programs have been reported to show low adherence. The MyoMobile study has been designed to assess the effect of a 12-week, app-based coaching program on physical activity in patients with HFpEF. Physical activity including daily step count will be assessed by accelerometry and, in addition, a pedometer will be used to measure the daily step count and provide direct feedback to the patient. Accelerometers provide an objective and continuous assessment of physical activity during patients' daily life over longer periods and may therefore reflect the true effect of the activity coaching intervention on physical activity more accurately than intermittent supervised exercise tests such as the six minute walk test. These efforts are complemented by a comprehensive (sub)clinical and molecular characterization of HFpEF patients at baseline and after the follow-up period of 12 weeks. In order to evaluate the potential effect of awareness for physical activity and of surveillance, due to participants wearing a pedometer throughout the study period, two intervention groups will be investigated. This will allow for the effect of an individualized, app-based coaching intervention, compared to standard care in patients with HFpEF, to be deciphered.

Study Type

OBSERVATIONAL

Enrollment

193

Conditions

Heart Failure Heart Failure, Diastolic

Interventions

App-based physical activity coachingBEHAVIORAL

Individualized app-based coaching via a smartphone

No Intervention: Observational CohortBEHAVIORAL

no Intervention

Intervention Group 1BEHAVIORAL

pedometer-based tracking of physical activity

Eligibility

Sex: ALLMin age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 45 years * Diagnosis of HFpEF * LVEF \> 40% by any imaging modality at screening within 4 months prior to study entry * Current HF symptoms as defined as presence of dyspnea according to New York Heart Association \[NYHA\] functional class I to III at screening visit * Stable HF treatment for at least 4 weeks prior to screening * At least one of the following 3 criteria need to be fulfilled: (1) NT-proBNP ≥ 300pg/ml; (2) Hospitalization for HF within the past 12 months; (3) Symptom(s) of HF requiring treatment with diuretic(s) for at least 30 days prior to screening visit * Wearing time of the physical activity monitor for at least 4 days during the baseline assessment * Average daily step count during baseline assessment ≥ 1,000 steps per day and \< 10,000 steps per day Exclusion Criteria: * Acute decompensated HF requiring augmented therapy with diuretic agents, vasodilator agents, and/or inotropic drugs * Participants who are non-ambulatory managed or use mobility assistive devices such as motorized devices or wheelchairs * Acute coronary syndrome (including myocardial infarction), cardiac surgery, other major cardiovascular surgery or urgent percutaneous coronary intervention (PCI) within 3 months prior to visit 1 or an elective PCI within 30 days after study enrolment * Probable alternative diagnoses that in the opinion of the investigator account for the patient's HF symptoms (i.e., dyspnea, fatigue) * Participants with physical activity impairment primarily due to conditions other than HF such as: * Participants unwilling or unable to wear or to operate study measurement devices for the phases required * Exertional angina * Inflammatory or degenerative joint disease * Peripheral vascular disease * Neurologic disease affecting activity or mobility (e.g. peripheral neuropathy) * Foot ulcer (e.g. diabetic foot syndrome) * Prosthetic limbs * Current chemotherapy and/or radiation therapy for treatment of active cancer * Medical or psychological conditions that would jeopardize an adequate and orderly conduct or completion of the study

Locations (1)

University Medical Center of the Johannes Gutenberg-University Mainz

Mainz, Rhineland-Palatinate, Germany

Outcomes

Primary Outcomes

Average daily step count (all groups)

The primary efficacy endpoint is the change in average daily step count between the baseline phase (mean of data collected during the period prior to randomization) and the end of the intervention (mean of data collected during week 12) comparing standard care to a 12-week individualized app-based activity coaching

Time frame: 12 weeks

Secondary Outcomes

Difference in E/E' ratio (change from baseline to 12-week follow-up)

Difference in E/E' ratio (change from baseline (V1) to 12-week follow-up (V4))

Time frame: 12 weeks

Difference in left ventricular ejection fraction (LVEF) from baseline to 12-week follow-up (V4)

Difference in LVEF (systolic function) from baseline to 12-week follow-up

Time frame: 12 weeks

Difference in quality of life (change from baseline to 12-week follow-up)

Difference in quality of life from baseline to 12-week follow-up (measured with The Kansas City Cardiomyopathy Questionnaire (KCCQ))

Time frame: 12 weeks

Difference in heart rate variability (HRV) (change from baseline to 12-week follow-up)

Difference in HRV from baseline to 12-week follow-up (measured with 24-hour Holter ECG)

Time frame: 12 weeks

Difference in peak VO2 (change from baseline to 12-week follow-up)

Difference in peak VO2 from baseline to 12-week follow-up (cardiopulmonary exercise testing)

Time frame: 12 weeks

Change in daily non-sedentary daytime activity from baseline to 12-week follow-up

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.